Skip to main content

Advertisement

SpringerLink
Log in

New Strategies in Chronic Myeloid Leukemia

  • Progress in Hematology
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Most patients with chronic myeloid leukemia (CML) achieve clinically relevant hematologic and cytogenetic responses to imatinib. Patients who show resistance to imatinib need new therapeutic options. A range of options are being developed to treat imatinib-resistant patients who have CML. Promising results of early-phase clinical trials have been reported for new tyrosine kinase inhibitors, farnesyl transferase inhibitors, decitabine, homoharringtonine, and vaccines. Further clinical trials are needed to characterize the efficacy and safety profile of these new agents and to determine which agents improve the long-term prognosis for patients with CML who have shown resistance to imatinib.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004.

    Article  PubMed  Google Scholar 

  2. Corbin AS, Rosee PL, Stoffregen EP, Druker BJ, Deininger MW. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood. 2003;101:4611–4614.

    Article  CAS  PubMed  Google Scholar 

  3. Donato NJ, Wu JY, Stapley J, et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res. 2004;64:672–677.

    Article  CAS  PubMed  Google Scholar 

  4. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7:129–141.

    Article  CAS  PubMed  Google Scholar 

  5. Kantarjian H, Ottman J, Cortes J, et al. AMN107, a novel aminopy-rimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant bcr-abl positive chronic myeloid leukemia (CML) [abstract]. J Clin Oncol. 2005;16:195s. Abstract 3014.

    Google Scholar 

  6. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47:6658–6661.

    Article  CAS  PubMed  Google Scholar 

  7. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399–401.

    Article  CAS  PubMed  Google Scholar 

  8. Talpaz M, Kantarjian H, Paquette R, et al. A phase I study of BMS-354825 in patients with imatinib-resistant and intolerant chronic phase chronic myeloid leukemia (CML): results from CA180002 [abstract]. J Clin Oncol. 2005;16S:564s. Abstract 6519.

    Google Scholar 

  9. Sawyers CL, Shah NP, Kantarjian H, et al. A phase I study of BMS-354825 in patients with imatinib-resistant and intolerant accelerated and blast phase chronic myeloid leukemia (CML): results from CA180002 [abstract]. J Clin Oncol. 2005;16S:565s. Abstract 6520.

    Google Scholar 

  10. O’Hare T, Pollock R, Stoffregen EP, et al. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood. 2004;104:2532–2539.

    Article  CAS  PubMed  Google Scholar 

  11. Golas JM, Arndt K, Etienne C, et al. SKI-606, a 4-anilino-3-quino-linecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 2003;63:375–381.

    PubMed  CAS  Google Scholar 

  12. Warmuth M, Simon N, Mitina O, et al. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood. 2003;101:664–672.

    Article  CAS  PubMed  Google Scholar 

  13. Sun X, Layton JE, Elefanty A, Lieschke GJ. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL-expressing cells, demonstrating synergy between AG490 and STI571. Blood. 2001;97:2008–2015.

    Article  CAS  PubMed  Google Scholar 

  14. Mow BM, Chandra J, Svingen PA, et al. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood. 2002;99:664–671.

    Article  CAS  PubMed  Google Scholar 

  15. Gumireddy K, Baker SJ, Cosenza SC, et al. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci U S A. 2005;102:1992–1997.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Gumireddy K, Reddy MV, Cosenza SC, et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anti-cancer agent. Cancer Cell. 2005;7:275–286.

    Article  CAS  PubMed  Google Scholar 

  17. Cortes J, Albitar M, Thomas D, et al. Efficacy of the farnesyl trans-ferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood. 2003;101:1692–1697.

    Article  CAS  PubMed  Google Scholar 

  18. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 2001;97:3361–3369.

    Article  CAS  PubMed  Google Scholar 

  19. Cortes J, Daley GQ,Talpaz M, et al. Pilot study of SCH66336 (lon-afarnib), a farnesyl transferase inhibitor (FTI), in patients with chronic myeloid leukemia (CML) in chronic or accelerated phase resistant or refractory to imatinib [abstract]. Blood. 2002;100:164a. Abstract 614.

    Article  Google Scholar 

  20. Cortes J, Garcia-Manero G, O’Brien S, et al. A phase I study of tip-ifarnib in combination with imatinib mesylate for patients with chronic myeloid leukemia in chronic phase who failed IM therapy [abstract]. Blood. 2004;104. Abstract 1011.

    Google Scholar 

  21. Gotlib J, Mauro MJ, O’Dwyer M, et al. Tipifarnib (Zarnestra) and imatinib (Gleevec) combination therapy in patients with advanced chronic myelogenous leukemia (CML): preliminary results of a phase I study [abstract]. Blood. 2003;102:909a. Abstract 3384.

    Google Scholar 

  22. Cortes J, O’Brien S, Verstovsek S, et al. Phase I study of lonafarnib (SCH66336) in combination with imatinib for patients with chronic myeloid leukemia (CML) after failure to imatinib [abstract]. Blood. 2004;104. Abstract 1009.

  23. Kantarjian HM, O’Brien S, Cortes J, et al. Results of decitabine (5-aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer. 2003;98:522–528.

    Article  CAS  PubMed  Google Scholar 

  24. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004;103:1635–1640.

    Article  CAS  PubMed  Google Scholar 

  25. Issa JP, Garcia-Manero G, Talpaz M, et al. Phase II Study of 5-aza-2′-deoxycytidine (decitabine) in patients with Philadelphia chromosome positive chronic myelogenous leukemia resistant or intolerant to imatinib mesylate [abstract]. Blood. 2003;102:910a. Abstract 3385.

    Google Scholar 

  26. O’Brien S, Kantarjian H, Keating M, et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood. 1995;86:3322–3326.

    PubMed  Google Scholar 

  27. O’Brien S, Giles F, Talpaz M, et al. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer. 2003;98:888–893.

    Article  CAS  PubMed  Google Scholar 

  28. Cortes J, O’Brien S, Verstovsek S, et al. Phase I study of subcutaneous (SC) homoharringtonine (HHT) for patients (pts) with chronic myelogenous leukemia (CML) [abstract]. In: program and abstracts of the 45th Annual Meeting and Exposition of the American Society of Hematology; December 6–9,2003; San Diego, Calif, USA. Abstract 5010.

  29. Marin D, Kaeda JS, Andreasson C, et al. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer. 2005;103:1850–1855.

    Article  CAS  PubMed  Google Scholar 

  30. Pinilla-Ibarz J, Cathcart K, Korontsvit T, et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood. 2000;95:1781–1787.

    PubMed  CAS  Google Scholar 

  31. Cathcart K, Pinilla-Ibarz J, Korontsvit T, et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood. 2004;103:1037–1042.

    Article  CAS  PubMed  Google Scholar 

  32. Bocchia M, Gentili S, Abruzzese E, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet. 2005;365:657–662.

    Article  CAS  PubMed  Google Scholar 

  33. Qazilbash MH, Wieder E, Rios R, et al. Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia [abstract]. Blood. 2004;104:77a. Abstract 259.

    Google Scholar 

  34. Li Z, Qiao Y, Laska E, et al. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein 70 vaccine for chronic myelogenous leukemia [abstract]. Proc Am Soc Clin Oncol. 2003;22:166. Abstract 664.

    Google Scholar 

  35. Choi YJ, Wang Q, White S, Gorre ME, Sawyers CL, Bollag G. Ima-tinib-resistant cell lines are sensitive to the Raf inhibitor BAY 43-9006 [abstract]. Blood. 2002;100:369a. Abstract 1427.

    Article  CAS  Google Scholar 

  36. Yu C, Krystal G, Varticovksi L, et al. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergisti-cally with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res. 2002;62:188–199.

    PubMed  CAS  Google Scholar 

  37. Sattler M, Mohi MG, Pride YB, et al. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell. 2002;1:479–492.

    Article  CAS  PubMed  Google Scholar 

  38. Sekulic A, Hudson CC, Homme JL, et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 2000;60:3504–3513.

    PubMed  CAS  Google Scholar 

  39. Mohi MG, Boulton C, Gu TL, et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A. 2004;101:3130–3135.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Yu C, Krystal G, Dent P, Grant S. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. Clin Cancer Res. 2002;8:2976–2984.

    PubMed  CAS  Google Scholar 

  41. Scherr M, Battmer K,Winkler T, Heidenreich O, Ganser A, Eder M. Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood. 2003;101:1566–1569.

    Article  CAS  PubMed  Google Scholar 

  42. Wohlbold L, van der Kuip H, Miething C, et al. Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for ima-tinib mesylate (STI571). Blood. 2003;102:2236–2239.

    Article  CAS  PubMed  Google Scholar 

  43. Nimmanapalli R, O’Bryan E, Bhalla K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res. 2001;61:1799–1804.

    PubMed  CAS  Google Scholar 

  44. Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood. 2002;100:3041–3044.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas, USA

    Hagop M. Kantarjian & Jorge Cortes

Authors
  1. Hagop M. Kantarjian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jorge Cortes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hagop M. Kantarjian.

About this article

Cite this article

Kantarjian, H.M., Cortes, J. New Strategies in Chronic Myeloid Leukemia. Int J Hematol 83, 289–293 (2006). https://doi.org/10.1532/IJH97.06024

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1532/IJH97.06024

Key words

Search

Navigation